CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← TALPHERA, INC. (TLPH) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

TALPHERA, INC. (TLPH)

Pharmaceutical Preparations · market cap $61M · as of 2026-07-16

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-12-31
Regulatory
Pipeline
8
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Talphera, Inc. (TLPH) is a micro-cap pharmaceutical company focused on sublingual sufentanil formulations for acute and post-operative pain, with a lead asset (sufentanil sublingual 30 mcg tablet) in Phase 3 and an estimated NDA filing in early 2027. The company carries a $73M market cap but holds only $3.8M in cash — roughly 3.4 months of runway — creating acute financing risk ahead of any regulatory milestone.
The catalyst path
  • 2026-12-31Regulatoryimp 5/10
  • 2027-01-01 (est.)NDA Filingimp 6/10
Pipeline
AssetPhaseIndication
sufentanil sublingualPhase 3Moderate-to-severe Acute Pain
Oral sufentanilPhase 2Major Upper or Lower Abdominal Surgery
Sufentanil NanoTab PCA SystemPhase 3Pain, Postoperative
Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03)Phase 2Sedation
Zalviso™Phase 3Moderate-to-severe Acute Pain
SufentanilPhase 3Post-Operative Pain
Sufentanil NanoTabPhase 2Post Operative Pain
morphine IV PCAPhase 3Post-Operative Pain
Price & technical context
3-month
-29.8%
6-month
+6.2%
12-month
-19.0%
52-wk range
$0.72–$1.47
vs 50-day MA
-22.9%
vs 200-day MA
-16.1%
Realized vol
67.5%
Max drawdown
-62.5%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for TLPH (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.